

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

NCT07226791

| | |
|------------|------------------|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | AbbVie |
| Enrollment | 200 participants |

Key Eligibility Criteria

Inclusion (1)

- Midline ventral hernia requiring open surgical repair.

Exclusion (2)

- Medical condition that may put the participant at increased risk with exposure to AGN-151607-DP, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease which might interfere with neuromuscular function.
- History of abdominal or hernia repair surgery requiring hospitalization within 6 months prior to screening.

Locations (3 total)

University of Florida - Jacksonville /ID# 261992, Jacksonville, Florida, United States
Medical Research Center /ID# 278680, Miami, Florida, United States
NextStage Clinical Research-Evergreen Surgical /ID# 278710, Eau Claire, Wisconsin, United States